法罗培南治疗细菌性呼吸道感染的临床研究  

Clinical study of faropenem in the treatment of bacterial respiratory tract infections

作　　者：隋玉玲[1] 李学堂[1] 

机构地区：[1]山东省临沂市沂水中心医院,276400

出　　处：《临床合理用药杂志》2012年第32期10-11,共2页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的评价国产法罗培南治疗细菌性呼吸道感染的疗效和安全性。方法将64例细菌性呼吸道感染患者随机分为试验组和对照组各32例。试验组予以法罗培南钠口服治疗,对照组予以头孢呋辛酯口服治疗,疗程均为6～14d。比较2组临床疗效、细菌学疗效及不良反应发生率。结果试验组和对照组痊愈率分别为78.1%和81.3%,总有效率分别为96.9%和93.7%;细菌清除率分别为92.8%和88.9%;不良反应发生率分别为6.3%和6.3%,差异均无统计学意义(P>0.05)。结论国产法罗培南治疗细菌性呼吸道感染安全、有效,与头孢呋辛酯相仿。Objective To evaluate the clinical efficacy and safety of domestic faropenem in the treatment of respirato- ry tract bacterial infections. Methods 64 cases of patients with respiratory infection were divided into experimental group and control group, each of 32 cases. The experimental group received faropenem tablets, while the control group received cefuroxime axetil tablets for 6 to 14 d. The clinical effect, bacteriology curative effect and adverse reaction ratio of 2 groups were compared. Results The cure and effective rates were 78.1% and 96.9% in experimental group, and were 81.3% and 93.7% in control group. The bacterial eradication rates were 92.8% ,88.9% ,and the adverse events rates were 6.3% ,6.3% in the experimen- tal group and the control groups respectively. There were no significant differences of above datas between 2 groups （P 〉 0. 05 ）. Conclusion Domestic faropenem is effective and safe for the treatment of bacterial respiratory tract infections.

关 键 词：法罗培南 头孢呋辛酯 呼吸道感染 细菌性 

分 类 号：R56[医药卫生—呼吸系统]